Novel NLRP3 Inhibitors for Steroid Resistant Asthma

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1118973

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Asthma causes 40,000 hospitalisations p.a. with 5-10% of asthmatics having severe steroid resistant asthma, a common and debilitating disease, where current treatments do not work. Effective therapies are urgently required. Based on our research, we have novel molecules showing high level of efficacy in models of severe steroid resistant asthma. These molecules will be further investigated to deliver a drug candidate for commercialisation within 3 years.

Funded Activity Details

Start Date: 01-01-2017

End Date: 01-01-2019

Funding Scheme: Development Grants

Funding Amount: $927,117.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Biologically Active Molecules

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

asthma therapy | drug discovery | inflammatory diseases | innate immunity | medicinal chemistry

Related Links